Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment
Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.
Allurion Technologies’ gastric balloon+GLP1s may become new SOC, says Roth MKM
Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.
Allurion Technologies balloon data ‘intriguing,’ says Chardan
Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...
Allurion Shares Surge 40% on Positive Results from Weight-Loss Study
Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...
Morningstar3d
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% ...
Investing3d
Allurion reports weight loss and muscle gain with new therapy
NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical company focused on obesity treatment currently trading near its 52-week low at $2.27, has announced promising initial results ...
US Stocks Likely To Open Lower, But 'Economic Conditions Don't Signal A Downturn,' Say Analysts As They Expect 'Resilient Earnings' To Lift Equities
U.S. stock futures declined on Friday after tumbling in trade on Thursday. Futures of all four indices were lower in ...
Nasdaq6d
ALLURION TECHNOLOGIES Earnings Preview: Recent $ALUR Insider Trading, Hedge Fund Activity, and More
ALLURION TECHNOLOGIES ($ALUR) is expected to release its quarterly earnings data on Wednesday, March 19th before market open, per Finnhub. Analysts are expecting ...
Benzinga.com2d
US Stocks Likely To Open Lower, But 'Economic Conditions Don't Signal A Downturn,' Say Analysts As They Expect 'Resilient Earnings' To Lift Equities
Allurion Technologies Inc. ALUR climbed 40.79% after its combined obesity treatment drug showed a significant 20.3% weight loss in initial trials. Patriot National Bancorp Inc. PNBK gained 51.89% ...